meta|evidence COVID-19

Living systematic review and meta-analysis

adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
A EFFACER BBV152 (Bharat Biotech, India)
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)
A EFFACER_ Vero cell
A EFFACER_sequential Immunization
BCG vaccination
complete primary vaccine series
CoVLP (MT-2766, Medicago)
DNA vaccine
ebola vaccine
first booster dose
heterologous prime-boost
Inactivated virus vaccine
mRNA vaccine
Non replicating viral vector
protein subunit vaccine
Replicating Viral Vector
seasonal influenza vaccines
second booster dose
virus-like particles vaccine
Vitamins

potential COVID-19 treatments
control

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention

patient subgroup...
alpha variant (B.1.1.7, UK)
delta variant (B.1.617.2, Indian)
immunodepression
omicron variant BA.1 (B.1.1.529)
omicron variant BA.2 VOC

Studies
Mapping
Meta-analysis
Excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -